Osteoarthritis Patents (Class 514/16.8)
  • Patent number: 11090301
    Abstract: The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: August 17, 2021
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Patent number: 10835566
    Abstract: The present invention relates to a composition comprising curcuminoid with green tea polyphenol or with a combination of glycine, proline and hydroxyproline for use in preventing or treating osteoarthritis. It also relates to a method of preventing or treating osteoarthritis in mammals, the method comprising administering to said mammal a composition which comprises curcuminoid with green tea polyphenol or with a combination of glycine, proline and hydroxyproline.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: November 17, 2020
    Assignee: Mars, Incorporated
    Inventors: Samuel Serisier, Fanny Comblain, Yves Henrotin
  • Patent number: 10712319
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: July 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • Patent number: 9956217
    Abstract: The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Patent number: 9932443
    Abstract: The subject invention pertains to peptide-based materials comprising cross-linked peptides with random amino acid sequences that are soluble in water or ethanol before crosslinking but insoluble in water after crosslinking.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: April 3, 2018
    Assignee: University of South Florida
    Inventor: Donald T Haynie
  • Patent number: 9334308
    Abstract: Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of Placenta Immunomodulatory Factor (PLIF) to human leukocytes.
    Type: Grant
    Filed: March 10, 2013
    Date of Patent: May 10, 2016
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventor: Chaya Moroz
  • Publication number: 20150132365
    Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 14, 2015
    Applicant: N.V. Nutricia
    Inventors: Thomas Ludwig, Sylvie Huybers, Evan Abrahamse, Houkje Bouritius
  • Publication number: 20150104485
    Abstract: Compounds of general formula (I): Ri—Wn—Xm-AAi-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, pigmentation disorders and angiogenic skin disorders, and in processes of treatment and/or care of the skin and/or mucous membranes.
    Type: Application
    Filed: April 16, 2013
    Publication date: April 16, 2015
    Applicant: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Jose Maria Garcia Anton, Antonio Vicente Ferrer Montiel, Cristina Carreño Serraïma, Raquel Delgado González, Juan Cebrián Puche
  • Patent number: 8987201
    Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: March 24, 2015
    Assignee: Michigan Technological University
    Inventor: Seth W. Donahue
  • Patent number: 8987204
    Abstract: It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: March 24, 2015
    Assignee: FUJIFILM Coporation
    Inventors: Takahiro Hiratsuka, Shouji Ooya, Ichiro Nishimura
  • Patent number: 8980834
    Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: March 17, 2015
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, James V. Winkler
  • Patent number: 8975225
    Abstract: The invention relates to peptides useful for inhibiting IGF-1 activity and their use as agents for inhibition of in vitrocell proliferation and for treatment of various diseases.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: March 10, 2015
    Assignee: Universite Pierre et Marie Curie (Paris 6)
    Inventors: Claude Carelli, Zvi Laron, Gila Maor
  • Publication number: 20150065427
    Abstract: Provided are methods for treating a pathological condition associated with unbalanced osteoclast differentiation by providing an AQP-9 modulator. The modulator can be an AQP-9 inhibitor or an AQP-9 inducer. Also provided are methods for modulating osteoclast differentiation, methods for treating pathological conditions associated with unbalanced osteoclast differentiation, as well as pharmaceutical composition including such modulators.
    Type: Application
    Filed: September 12, 2014
    Publication date: March 5, 2015
    Applicant: OSTEOBUILD LTD.
    Inventors: Zvi BAR-SHAVIT, Refael AHARON
  • Publication number: 20150057229
    Abstract: A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosed
    Type: Application
    Filed: September 9, 2014
    Publication date: February 26, 2015
    Inventors: Anthony Day, Caroline Milner, Sheona Patricia Drummond
  • Publication number: 20150045302
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Angelo Corti, Flavio Curnis
  • Publication number: 20150037350
    Abstract: The invention provides means for treating Th1- and Th2-mediated diseases, such as asthma, allergic dermatitis and Th2-driven cancer. The invention extends to pharmaceutical compositions for use in treating such conditions, and to methods of treatment. The invention also extends to adjuvants and vaccines per se, and to their use in enhancing the immunomodulatory activity of immunogens.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 5, 2015
    Applicant: UCL BUSINESS PLC
    Inventors: Anna L. Furmanski, Jose Ignacio Saldana, Tessa Crompton
  • Publication number: 20150018279
    Abstract: The invention relates to compositions and methods for the treatment of inflammatory disease states. In particular, the invention relates to the use of a nanoparticle incorporated kinase inhibiting peptide to treat inflammatory disease states.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 15, 2015
    Inventors: Alyssa Panitch, Brandon Seal, Jamie L. Brugnano, Rush L. Bartlett, Shaili Sharma, James Mcmasters
  • Patent number: 8932651
    Abstract: The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic treatment of a chronic inflammatory disorder. Further, the invention relates to a clinical food product comprising heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 13, 2015
    Assignee: Alfa Biogene International B.V.
    Inventors: Julia Lax, Federico G. Seifarth
  • Publication number: 20150011458
    Abstract: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
    Type: Application
    Filed: June 17, 2014
    Publication date: January 8, 2015
    Inventors: Jan-Eric Ahlfors, Khalid Mekouar
  • Patent number: 8927491
    Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: January 6, 2015
    Assignee: DePuy Mitek, LLC
    Inventors: Benjamin A. Byers, Dongling Su, Julia Hwang
  • Publication number: 20150004165
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Application
    Filed: September 8, 2014
    Publication date: January 1, 2015
    Applicant: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Patent number: 8920838
    Abstract: Provided are methods for the treatment of a rheumatic disease, such as rheumatoid arthritis, ankylosating spondylitis and/or polymyalgia rheumatic, by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks. Also provided are methods for the treatment of osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof wherein the treatment is administered once daily for at least about two weeks.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: December 30, 2014
    Assignee: Horizon Pharma AG
    Inventor: Achim Schaeffler
  • Publication number: 20140369984
    Abstract: The present disclosure provides biomaterials and methods for preventing and minimizing progression of cartilage and/or connective tissue damage. Also provided herein are biomaterials and methods for alleviating and/or reducing the risk for developing arthritis (e.g., osteoarthritis) associated with joint injury and/or joint surgery.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 18, 2014
    Applicants: Children's Medical Center Corporation, Rhode Island Hospital
    Inventors: Martha M. Murray, Braden C. Fleming
  • Publication number: 20140364359
    Abstract: The invention provides di-peptide conjugated antitumor agents, pharmaceutical compositions and methods for preparation and use thereof for treating various cancer and inflammation-related diseases and conditions. The present invention addresses the shortcomings of the existing anti-tumor and anti-inflammatory drugs, particularly in that the anti-tumor agents of the invention that selectively kill cancer cells with minimal damage to normal cells.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 11, 2014
    Inventor: Raymond A FIRESTONE
  • Publication number: 20140364371
    Abstract: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 11, 2014
    Inventors: Lori A. Setton, Ashutosh Chilkoti, Virginia B. Kraus, Helawe Betre, Matthew R. Dreher
  • Patent number: 8906966
    Abstract: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 9, 2014
    Inventors: Paul Sherwood, David Keith Davies
  • Publication number: 20140357557
    Abstract: Methods and compositions relating to CDP-JAK inhibitor conjugates are described herein.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventors: Roderic O. Cole, Derek Gregory van der Poll
  • Patent number: 8900579
    Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 2, 2014
    Assignee: Alethia Biotherapuetics Inc.
    Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
  • Patent number: 8895506
    Abstract: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: November 25, 2014
    Assignee: DePuy Synthes Products, LLC
    Inventors: Venkata R. Garigapati, Dongling Su, Rehan Khanzada, Steven J. Sawamura
  • Publication number: 20140342983
    Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 20, 2014
    Inventors: Marina D'Angelo, Abdulhafez Selim
  • Patent number: 8877712
    Abstract: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells, whereby survival or differentiation of chondrocytes at the site is enhanced, thereby ultimately enhancing bone density or formation. Methods and compositions for stimulating hair regrowth are also provided.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: November 4, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: George P Yang, Jonathan A. Mathy, Thomas Quertermous
  • Patent number: 8859505
    Abstract: Compounds of the formula I wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a C5-C10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; or R3 is a C2-C4alkyl chain with at least 2 chloro or 3 fluoro substituents; or R3 is C3-C7cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C1-C4alkyl, halo, C1-C4haloalkyl, C1-C4alkoxy, C1-C4haloalkoxy; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylamino, C1-C6dialkylamino or; R4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R4 is Het, carbocyclyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy or C1-C6haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of ca
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: October 14, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Urszula Grabowska, Ellen Hewitt, Daniel Jonsson, Bjorn Klasson, Pia Kahnberg, Stina Lundgren, Jan Tejbrant, Daniel Wiktelius
  • Publication number: 20140303080
    Abstract: N-acyldipeptide derivatives are described. Compositions comprising the N-acyldipeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with a tumor, cancer, immune, nervous, vascular, musculoskeletal or cutaneous system, or other tissue or system in a subject.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 9, 2014
    Inventors: Ruey J. Yu, Eugene J. Van Scott
  • Publication number: 20140301983
    Abstract: This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.
    Type: Application
    Filed: May 24, 2012
    Publication date: October 9, 2014
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Alyssa Panitch, Jonathan C. Bernhard, John E. Paderi, Shaili Sharma
  • Publication number: 20140271589
    Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: BIOMET BIOLOGICS, LLC
    Inventors: Andrea MATUSKA, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY
  • Patent number: 8835390
    Abstract: The present invention concerns the use of an aquaprin-9 (AQP-9) modulator for the preparation of a pharmaceutical composition for treating or preventing a pathological condition associated with unbalanced osteoclast differentiation. In accordance with one embodiment, the modulator is an AQP-9 inhibitor. An example of AQP-9 inhibitor is phloretin which has been shown to inhibit osteoclast differentiation, following induction of bone marrow cells with RANKL. The invention also concerns methods for modulating osteoclast differentiation, methods for prevention and treating pathological conditions associated with unbalanced osteoclast differentiation as well as pharmaceutical composition comprising such modulators.
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: September 16, 2014
    Assignee: Osteobuild Ltd.
    Inventors: Zvi Bar-Shavit, Refael Aharon
  • Publication number: 20140256642
    Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Application
    Filed: October 10, 2012
    Publication date: September 11, 2014
    Inventors: David Bar-Or, James V. Winkler
  • Publication number: 20140255374
    Abstract: Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.
    Type: Application
    Filed: November 6, 2013
    Publication date: September 11, 2014
    Applicant: CERULEAN PHARMA INC.
    Inventor: Scott Eliasof
  • Patent number: 8828937
    Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: September 9, 2014
    Assignee: Haase Investments UG
    Inventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
  • Publication number: 20140234301
    Abstract: The present invention provides methods of using PILR? agonists, or PILR? antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Cristina M. Tato, Barbara Joyce-Shaikh, Daniel J. Cua
  • Publication number: 20140235544
    Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 21, 2014
    Inventor: Yitzchak Hillman
  • Publication number: 20140219981
    Abstract: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.
    Type: Application
    Filed: January 14, 2014
    Publication date: August 7, 2014
    Applicant: Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Hanna RAPAPORT
  • Publication number: 20140221271
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Application
    Filed: June 5, 2012
    Publication date: August 7, 2014
    Inventors: Shawn P Iadonato, Eric J Tarcha
  • Publication number: 20140213523
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include Amyotrophic Lateral Sclerosis (ALS), as well as muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Application
    Filed: October 9, 2013
    Publication date: July 31, 2014
    Applicant: Tivorsan Pharmaceuticals, Inc.
    Inventors: Justin Fallon, Elizabeth John
  • Publication number: 20140200174
    Abstract: Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the delay of the onset of ischemic diseases and the therapy of ischemic diseases.
    Type: Application
    Filed: January 13, 2014
    Publication date: July 17, 2014
    Applicant: Chonnam National University Hospital
    Inventors: Taek Rim YOON, Hyung Keun KIM, Ji Hyun KIM, Myung Ho JEONG
  • Publication number: 20140194343
    Abstract: [Problem] The topic of the present invention is the elucidation of the biological function of CTRP6 and its application. [Solution] A pharmaceutical composition containing CTRP6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided.
    Type: Application
    Filed: May 9, 2012
    Publication date: July 10, 2014
    Applicant: THE UNIVERSITY OF TOKYO
    Inventors: Yoichiro Iwakura, Masanori Murayama, Harumichi Ishigame, Shigeru Kakuta
  • Publication number: 20140194342
    Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.
    Type: Application
    Filed: November 15, 2013
    Publication date: July 10, 2014
    Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, JR.
  • Patent number: 8765675
    Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: July 1, 2014
    Assignee: Novartis AG
    Inventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
  • Patent number: 8765678
    Abstract: A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed, in particular osteoarthritis and skin diseases. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: July 1, 2014
    Assignee: Mor Research Applications Ltd.
    Inventors: Talia Weinstein, Uzi Gafter, Zvi Nevo, Dror Robinson, Zoharia Evron
  • Patent number: 8754037
    Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 17, 2014
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song